NCT03445533 2022-11-08A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaIdera Pharmaceuticals, Inc.Phase 3 Terminated481 enrolled 22 charts
NCT01763164 2021-03-22Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaPfizerPhase 3 Completed402 enrolled 21 charts
NCT00434057 2012-02-14Evaluation of Pigmented Skin Lesions With MelaFind(R) SystemMELA Sciences, Inc.Phase 3 Completed1,383 enrolled 5 charts
NCT00094653 2011-07-11MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaBristol-Myers SquibbPhase 3 Completed1,783 enrolled 29 charts